VCEL Quote, Financials, Valuation and Earnings

Krystal Biotech, Inc. has a net margin of 25.02% compared to Vericel Corp.'s net margin of 47.99%. Vericel Corp.'s return on equity of 5.26% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

Vericel Corp. has a consensus price target of $55.43, signalling upside risk potential of 62.36%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $314.00 which suggests that it could grow by 20.33%. Given that Vericel Corp. has higher upside potential than Krystal Biotech, Inc., analysts believe Vericel Corp. is more attractive than Krystal Biotech, Inc..

Vericel Corp. has a beta of 1.204, which suggesting that the stock is 20.404% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.540, suggesting its less volatile than the S&P 500 by 46.017%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $92.9M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $107.1M. Vericel Corp.'s net income of $23.2M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Vericel Corp.'s price-to-earnings ratio is 116.03x while Krystal Biotech, Inc.'s PE ratio is 38.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 6.60x versus 20.22x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Marker Therapeutics, Inc. has a net margin of 25.02% compared to Vericel Corp.'s net margin of -154.36%. Vericel Corp.'s return on equity of 5.26% beat Marker Therapeutics, Inc.'s return on equity of -77.25%.

Vericel Corp. has a consensus price target of $55.43, signalling upside risk potential of 62.36%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 495.96%. Given that Marker Therapeutics, Inc. has higher upside potential than Vericel Corp., analysts believe Marker Therapeutics, Inc. is more attractive than Vericel Corp..

Vericel Corp. has a beta of 1.204, which suggesting that the stock is 20.404% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.471, suggesting its more volatile than the S&P 500 by 47.131%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $92.9M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.1M. Vericel Corp.'s net income of $23.2M is higher than Marker Therapeutics, Inc.'s net income of -$1.7M. Notably, Vericel Corp.'s price-to-earnings ratio is 116.03x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 6.60x versus 5.44x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 25.02% compared to Vericel Corp.'s net margin of -121.83%. Vericel Corp.'s return on equity of 5.26% beat Moderna, Inc.'s return on equity of -29.19%.

Vericel Corp. has a consensus price target of $55.43, signalling upside risk potential of 62.36%. On the other hand Moderna, Inc. has an analysts' consensus of $43.75 which suggests that it could fall by -11.08%. Given that Vericel Corp. has higher upside potential than Moderna, Inc., analysts believe Vericel Corp. is more attractive than Moderna, Inc..

Vericel Corp. has a beta of 1.204, which suggesting that the stock is 20.404% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.144%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $92.9M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Vericel Corp.'s net income of $23.2M is higher than Moderna, Inc.'s net income of -$826M. Notably, Vericel Corp.'s price-to-earnings ratio is 116.03x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 6.60x versus 9.69x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tenaya Therapeutics, Inc. has a net margin of 25.02% compared to Vericel Corp.'s net margin of --. Vericel Corp.'s return on equity of 5.26% beat Tenaya Therapeutics, Inc.'s return on equity of -87.41%.

Vericel Corp. has a consensus price target of $55.43, signalling upside risk potential of 62.36%. On the other hand Tenaya Therapeutics, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 1195.71%. Given that Tenaya Therapeutics, Inc. has higher upside potential than Vericel Corp., analysts believe Tenaya Therapeutics, Inc. is more attractive than Vericel Corp..

Vericel Corp. has a beta of 1.204, which suggesting that the stock is 20.404% more volatile than S&P 500. In comparison Tenaya Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tenaya Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. Tenaya Therapeutics, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $92.9M, which are larger than Tenaya Therapeutics, Inc. quarterly revenues of --. Vericel Corp.'s net income of $23.2M is higher than Tenaya Therapeutics, Inc.'s net income of -$20.2M. Notably, Vericel Corp.'s price-to-earnings ratio is 116.03x while Tenaya Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 6.60x versus -- for Tenaya Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.